Postmarketing surveillance for drug abuse.
Assessing actual abuse of prescribed medications requires postmarketing surveillance. In this article we discuss general systems of postmarketing surveillance that exist as of the end of 2002 in the United States and two medication-specific surveillance systems that were devised and tested. The two specific surveillance systems are compared with limitations highlighted. Postmarketing surveillance is in its infancy and requires more research on ways to improve its validity without inducing illicit experimentation. Information on comparator medications is highly recommended both to validate the system and to place the results in context.
Arfken
Cynthia L
CL
Department of Psychiatry and Behavioral Neurosciences, School of Medicine, Wayne State University, 2761 E. Jefferson, Detroit, MI 48207, USA. carfken@med.wayne.edu
Cicero
Theodore J
TJ
D016907:Adverse Drug Reaction Reporting Systems / Q000706:statistics & numerical data; D001067:Appetite Depressants / Q000494:pharmacology; D003503:Cyclobutanes / Q000494:pharmacology; D017277:Drug Approval; D006801:Humans; D009294:Narcotics / Q000494:pharmacology; D011358:Product Surveillance, Postmarketing / Q000379:methods*; D019966:Substance-Related Disorders / Q000209:etiology*; D011795:Surveys and Questionnaires; D014147:Tramadol / Q000494:pharmacology
D001067:Appetite Depressants; D003503:Cyclobutanes; D009294:Narcotics; D014147:Tramadol; C058254:sibutramine